SIGLEC1

Across TCGA pan-cancer cohorts, SIGLEC1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SIGLEC1 data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SIGLEC1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SIGLEC1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and OV show a favorable association.

CCRCC, UCEC, and HNSC are the cancer types where SIGLEC1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	II,III,IV	0.104	0.985	.024	21	view →
UCEC	DFS	Median	All	0.750	0.946	.012	10	view →
HNSC	OS	Median	II,III,IV	0.953	1.000	.019	10	view →
LSCC	OS	Median	III,IV	0.840	0.451	.015	8	view →
PDAC	DFS	Quartile	III,IV	0.600	0.917	.011	5	view →
OV	DFS	Median	All	0.919	0.553	.036	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SIGLEC1–CCRCC (OS)

Open the CCRCC breakdown →